Jasper Therapeutics

涉及Jasper Therapeutics的并购和融资。

• Jasper Therapeutics 刚刚宣布为 90 筹款数百万美元。 (公布2023一月31号).

查看带有其 20 名主要高管的组织结构图

Jasper Therapeutics 搜索最多的简介

• Ronald Martell, Chief Executive Officer and Director
• Anna French, Director
• Judith Shizuru, Director

高管在Jasper Therapeutics变化

• Svetlana Lucas已作为Director加入公司  (新闻发布的2024六月19号).

创建提醒
跟踪 Jasper Therapeutics 的高管变动

Jasper Therapeutics 拥有 2,327 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。

Popular M&A news in 生物技术

• Alentis Therapeutics 刚刚宣布为 181 筹款数百万美元。 (公布2024十一月20号).
• Metsera 刚刚宣布为 500 筹款数百万美元。 (公布2024十一月20号).
• TRexBio 刚刚宣布为 84 筹款数百万美元。 (公布2024十一月14号).

生物技术 行业的其他推荐联系人

• Scholar Rock 企业 Kristina Burow - Director
• UroGen 企业 Fred Cohen - Director
• Adaptimmune Therapeutics 企业 Ali Behbahani - Non-Executive Director

了解更多有关生物技术行业的信息 >

Jasper Therapeutics 的最新新闻稿

• News Releases | Jasper Therapeutics, Inc
• News Releases | Jasper Therapeutics, Inc
• Jasper Therapeutics and Aruvant Announce Research Collaboration to Study JSP191, an Antibody-Based Conditioning Agent, with ARU-1801, a Novel Gene Therapy for the Treatment of Sickle Cell Disease
• Jasper Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for JSP191 for Conditioning Treatment Prior to Stem Cell Transplant | Business Wire
• Jasper Therapeutics to Host Webcast to Review Updated 90-day Data from Phase 1 Clinical Trial of JSP191 That is Being Presented at 2021 ASCO Virtual Annual Meeting | Business Wire
• Jasper Therapeutics Announces New Clinical Trial with the National Institute of Allergy and Infectious Diseases to Evaluate JSP191 in Chronic Granulomatous Disease | Business Wire
• Jasper Therapeutics Announces Updated 90-day Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation | Bus
• Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Merger to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation | Business Wire
• Jasper Therapeutics Announces Launch of New Clinical Trial with National Heart, Lung, and Blood Institute to Evaluate JSP191 in Sickle Cell Disease | Business Wire
• Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation | Business Wire
• View more press releases Close

关于 Jasper Therapeutics 的社交媒体

• Jasper Therapeutics 在 维基百科、谷歌新闻 和 雅虎财经
• Jasper Therapeutics 在 LinkedIn、叽叽喳喳 和 YouTube

通过电子邮件联系联系该企业高管，包括 Anna French

致电Jasper Therapeutics，电话：+1 165 ...

查看组织结构图

Register to receive your alert

报告错误